 |
3-(4-(1,5-Napthrydine)-Imidazole[1,2-a]pyridine-7-(1-phenyl-4-(1-(4-methyl piperazine) |
|---|---|
| Trade Name | |
| Orphan Indication | Fibrodysplasia ossificans progressiva |
| USA Market Approval | USA |
| USA Designation Date | 2015-07-14 00:00:00 |
| Sponsor | La Jolla Pharmaceutical Company, Inc.;10182 Telesis Court, Suite 600;San Diego, California, 92121 |
